- •Sodium-glucose cotransporter 2 (SGLT2) inhibitors showed significant reductions in fatty liver index (FLI) and its components compared to dipeptidyl peptidase 4 (DPP4) inhibitors in type 2 diabetes patients.
- •We further analyzed the change in FLI according to drug adherence measured by the medication possession ratio, and the change increased cumulatively with the duration of drug use.
- •We suggest that SGLT2 inhibitors may have beneficial effects in reducing the prevalence of nonalcoholic fatty liver disease in type 2 diabetes.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Diabetes Research and Clinical Practice
- American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the american association for the study of liver diseases (AASLD).Endocr Pract. 2022; 28: 528-562
- Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications.Hepatology. 2010; 51: 679-689https://doi.org/10.1002/hep.23280
Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012;142:711–25 e6. doi: 10.1053/j.gastro.2012.02.003.
- The natural history of nonalcoholic fatty liver disease: a population-based cohort study.Gastroenterology. 2005; 129: 113-121
- State-of-the-art overview of the pharmacological treatment of non-alcoholic steatohepatitis.Endocrinol Metab (Seoul). 2022; 37: 38-52
- Mechanisms linking obesity to insulin resistance and type 2 diabetes.Nature. 2006; 444: 840-846https://doi.org/10.1038/nature05482
- Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause.Diabetologia. 2008; 51: 1781-1789https://doi.org/10.1007/s00125-008-1116-7
- The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments.Nat Rev Gastroenterol Hepatol. 2021; 18: 599-612https://doi.org/10.1038/s41575-021-00448-y
- The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis.J Hepatol. 2019; 71: 793-801
- Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action.Diabetes Care. 2017; 40: 419-430https://doi.org/10.2337/dc16-1787
Tacelli M, Celsa C, Magro B, Giannetti A, Pennisi G, Spatola F, et al. Antidiabetic drugs in NAFLD: the accomplishment of two goals at Once? Pharmaceuticals (Basel) 2018;11. doi: 10.3390/ph11040121.
- Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.Eur J Pharmacol. 2013; 715: 246-255
- Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus.Diabetol Metab Syndr. 2015; 7https://doi.org/10.1186/s13098-015-0102-8
- Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.Diabetologia. 2018; 61: 1923-1934
- Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial).Diabetes Care. 2018; 41: 1801-1808
- Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label.Active-Controlled Trial Diabetes Care. 2017; 40: 1364-1372
- Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study.Diabetes Obes Metab. 2018; 20: 438-442
- Current trends of big data research using the Korean National Health Information Database.Diabetes Metab J. 2022; 46: 552-563https://doi.org/10.4093/dmj.2022.0193
- The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population.BMC Gastroenterol. 2006; 6: 33https://doi.org/10.1186/1471-230X-6-33
- External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study.Clin Gastroenterol Hepatol. 2013; 11: 1201-1204https://doi.org/10.1016/j.cgh.2012.12.031
- External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals.Eur J Endocrinol. 2014; 171: 561-569
- The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review.Int J Clin Pract. 2008; 62: 76-87https://doi.org/10.1111/j.1742-1241.2007.01630.x
- Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes.Diabetes Care. 2004; 27: 2149-2153https://doi.org/10.2337/diacare.27.9.2149
- Glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors and risk of nonalcoholic fatty liver disease among patients with type 2 diabetes.Diabetes Care. 2022; 45: 819-829https://doi.org/10.2337/dc21-1953
- Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.Nat Rev Endocrinol. 2020; 16: 556-577https://doi.org/10.1038/s41574-020-0392-2
- Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms.Obes Rev. 2018; 19: 1630-1641https://doi.org/10.1111/obr.12755
- SGLT2 versus DPP4 inhibitors for type 2 diabetes.Lancet Diabetes Endocrinol. 2013; 1: 168-170https://doi.org/10.1016/s2213-8587(13)70095-0
- Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.Diabetes Metab Res Rev. 2017; 33: e2818https://doi.org/10.1002/dmrr.2818
- Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c.Diabetes Obes Metab. 2010; 12: 83-92https://doi.org/10.1111/j.1463-1326.2010.01275.x
- DPP-4 inhibitors and lipids: systematic review and meta-analysis.Adv Ther. 2012; 29: 14-25https://doi.org/10.1007/s12325-011-0088-z
Komiya C, Tsuchiya K, Shiba K, Miyachi Y, Furuke S, Shimazu N, et al. Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction. PLoS One 2016;11:e0151511. doi: 10.1371/journal.pone.0151511.
- SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease.Trends Endocrinol Metab. 2022; 33: 424-442https://doi.org/10.1016/j.tem.2022.03.005
- SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection.Int J Mol Sci. 2022; 23: 3107
- The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus.Ann Transl Med. 2019; 7: 429
Honda Y, Imajo K, Kato T, Kessoku T, Ogawa Y, Tomeno W, et al. The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice. PLoS One 2016;11:e0146337. doi: 10.1371/journal.pone.0146337.
- Second-line therapy for type 2 diabetes management: the treatment/benefit paradox of cardiovascular and kidney comorbidities.Diabetes Care. 2021; 44: 2302-2311https://doi.org/10.2337/dc20-2977
- The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).J Diabetes Complications. 2013; 27: 280-286https://doi.org/10.1016/j.jdiacomp.2012.12.004
- Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: a real-world data analysis.Liver Int. 2021; 41: 731-742
- Pharmacy claims data as a tool to measure adherence.Curr Med Res Opin. 2012; 28: 1389-1393https://doi.org/10.1185/03007995.2012.705781